• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

iScience . SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity

tetano

Editor, Senior Moderator
iScience


. 2024 Aug 23;27(10):110624.
doi: 10.1016/j.isci.2024.110624. eCollection 2024 Oct 18. SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity

Elizabeth J Martinez[SUP] 1 2 [/SUP], William C Chang[SUP] 1 2 [/SUP], Wei-Hung Chen[SUP] 1 2 [/SUP], Agnes Hajduczki[SUP] 1 2 [/SUP], Paul V Thomas[SUP] 1 2 [/SUP], Jaime L Jensen[SUP] 1 2 [/SUP], Misook Choe[SUP] 1 2 [/SUP], Rajeshwer S Sankhala[SUP] 1 2 [/SUP], Caroline E Peterson[SUP] 1 2 [/SUP], Phyllis A Rees[SUP] 1 2 [/SUP], Jordan Kimner[SUP] 2 3 [/SUP], Sandrine Soman[SUP] 3 [/SUP], Caitlin Kuklis[SUP] 3 [/SUP], Letzibeth Mendez-Rivera[SUP] 2 4 [/SUP], Vincent Dussupt[SUP] 2 4 [/SUP], Jocelyn King[SUP] 1 2 [/SUP], Courtney Corbett[SUP] 1 2 [/SUP], Sandra V Mayer[SUP] 1 2 [/SUP], Aldon Fernandes[SUP] 5 [/SUP], Kripa Murzello[SUP] 6 [/SUP], Tres Cookenham[SUP] 6 [/SUP], Janine Hvizdos[SUP] 6 [/SUP], Larry Kummer[SUP] 6 [/SUP], Tricia Hart[SUP] 6 [/SUP], Kathleen Lanzer[SUP] 6 [/SUP], Julian Gambacurta[SUP] 6 [/SUP], Matthew Reagan[SUP] 6 [/SUP], Debbie Duso[SUP] 6 [/SUP], Sandhya Vasan[SUP] 1 2 [/SUP], Natalie D Collins[SUP] 1 [/SUP], Nelson L Michael[SUP] 7 [/SUP], Shelly J Krebs[SUP] 4 [/SUP], Gregory D Gromowski[SUP] 3 [/SUP], Kayvon Modjarrad[SUP] 1 [/SUP], John Kaundinya[SUP] 8 [/SUP], M Gordon Joyce[SUP] 1 2 [/SUP]



Affiliations
Abstract

The rapid emergence of SARS-CoV-2 variants of concern (VoC) and the threat of future zoonotic sarbecovirus spillover emphasizes the need for broadly protective next-generation vaccines and therapeutics. We utilized SARS-CoV-2 spike ferritin nanoparticle (SpFN), and SARS-CoV-2 receptor binding domain ferritin nanoparticle (RFN) immunogens, in an equine model to elicit hyperimmune sera and evaluated its sarbecovirus neutralization and protection capacity. Immunized animals rapidly elicited sera with the potent neutralization of SARS-CoV-2 VoC, and SARS-CoV-1 pseudoviruses, and potent binding against receptor binding domains from sarbecovirus clades 1b, 1a, 2, 3, and 4. Purified equine polyclonal IgG provided protection against Omicron XBB.1.5 virus in the K18-hACE2 transgenic mouse model. These results suggest that SARS-CoV-2-based nanoparticle vaccines can rapidly produce a broad and protective sarbecovirus response in the equine model and that equine serum has therapeutic potential against emerging SARS-CoV-2 VoC and diverse sarbecoviruses, presenting a possible alternative or supplement to monoclonal antibody immunotherapies.

Keywords: Immunology; Virology.

 
Back
Top Bottom